Pharmaceuticals refer to compounds manufactured for use as a medicinal drug. Companies active in the pharmaceutical industry are involved in development, production and marketing of pharmaceuticals.
The global market for pharmaceuticals is demonstrating a substantial growth in Latin America and Asia, but is relatively stable in Europe. The worldwide market is assessed at about USD 300 billion yearly. The USA, Japan, Germany, France and China are the top pharmaceutical markets. The pharmaceutical industry benefits from the ageing population; new medical discoveries and new drugs approvals; the increased number of chronic, degenerative and heart diseases, and cancer.
The research reports of this Catalogue cover all the major categories within global, regional and local pharmaceuticals markets. The reports offer overviews of the market trends, drivers; factors contributing to market growth. The challenges faced by industry participants, analyses of the top companies involved in the marketplace, and the key market news are provided in the reports.
Publications found:
26,272
Sort by:
The 2027-2032 World Outlook for Hemarrhoid Treatments
US$ 1,195.00
This study covers the world outlook for hemarrhoid treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.)...
January 2026
287 pages
The 2027-2032 World Outlook for Hemophilia a Drugs
US$ 1,195.00
This study covers the world outlook for hemophilia a drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), f...
January 2026
287 pages
The 2027-2032 World Outlook for Hemophilia a Treatments
US$ 1,195.00
This study covers the world outlook for hemophilia a treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E...
January 2026
287 pages
The 2027-2032 World Outlook for Hemophilia Drugs
US$ 1,195.00
This study covers the world outlook for hemophilia drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for...
January 2026
287 pages
The 2027-2032 World Outlook for Hemophilia Treatments
US$ 1,195.00
This study covers the world outlook for hemophilia treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.)...
January 2026
287 pages
The 2027-2032 World Outlook for Heparin
US$ 1,195.00
This study covers the world outlook for heparin across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the coun...
January 2026
287 pages
The 2027-2032 World Outlook for Heparin Anticoagulants
US$ 1,195.00
This study covers the world outlook for heparin anticoagulants across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E....
January 2026
287 pages
The 2027-2032 World Outlook for Heparin Sodium
US$ 1,195.00
This study covers the world outlook for heparin sodium across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for t...
January 2026
287 pages
The 2027-2032 World Outlook for Hepatitis B Vaccines
US$ 1,195.00
This study covers the world outlook for hepatitis b vaccines across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.),...
January 2026
287 pages
The 2027-2032 World Outlook for Hepatitis C Drugs
US$ 1,195.00
This study covers the world outlook for hepatitis c drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), fo...
January 2026
287 pages
The 2027-2032 World Outlook for Hepatitis C Therapeutics
US$ 1,195.00
This study covers the world outlook for hepatitis c therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I....
January 2026
287 pages
The 2027-2032 World Outlook for Hepatitis Therapeutics
US$ 1,195.00
This study covers the world outlook for hepatitis therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E....
January 2026
287 pages
The 2027-2032 World Outlook for Herbal Medicinal Products
US$ 1,195.00
This study covers the world outlook for herbal medicinal products across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I...
January 2026
288 pages
The 2027-2032 World Outlook for Herbal Medicines
US$ 1,195.00
This study covers the world outlook for herbal medicines across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for...
January 2026
288 pages
The 2027-2032 World Outlook for High Potency APIs (HPAPIs)
US$ 1,195.00
This study covers the world outlook for high potency APIs (HPAPIs) across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P....
January 2026
287 pages
The 2027-2032 World Outlook for HIV-1 Therapeutics
US$ 1,195.00
This study covers the world outlook for HIV-1 therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), f...
January 2026
287 pages
The 2027-2032 World Outlook for HIV-AIDS Drugs
US$ 1,195.00
This study covers the world outlook for HIV-AIDS drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for t...
January 2026
287 pages
The 2027-2032 World Outlook for HIV Drugs
US$ 1,195.00
This study covers the world outlook for HIV drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the co...
January 2026
287 pages
The 2027-2032 World Outlook for HIV Therapeutics
US$ 1,195.00
This study covers the world outlook for HIV therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for...
January 2026
287 pages
The 2027-2032 World Outlook for Homeopathic Products
US$ 1,195.00
This study covers the world outlook for homeopathic products across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.),...
January 2026
287 pages
The 2027-2032 World Outlook for Homeopathy Products
US$ 1,195.00
This study covers the world outlook for homeopathy products across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.),...
January 2026
287 pages
The 2027-2032 World Outlook for Hospital Pharmaceuticals
US$ 1,195.00
This study covers the world outlook for hospital pharmaceuticals across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I....
January 2026
288 pages
The 2027-2032 World Outlook for HPAPIs
US$ 1,195.00
This study covers the world outlook for HPAPIs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the count...
January 2026
287 pages
The 2027-2032 World Outlook for HPV and CMV Therapeutics
US$ 1,195.00
This study covers the world outlook for HPV and CMV therapeutics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I....
January 2026
287 pages
The 2027-2032 World Outlook for HPV Vaccines
US$ 1,195.00
This study covers the world outlook for HPV vaccines across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the...
January 2026
287 pages
The 2027-2032 World Outlook for Human Growth Hormone Drugs
US$ 1,195.00
This study covers the world outlook for human growth hormone drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P....
January 2026
288 pages
The 2027-2032 World Outlook for Human Growth Hormones
US$ 1,195.00
This study covers the world outlook for human growth hormones across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.)...
January 2026
287 pages
The 2027-2032 World Outlook for Hunter Syndrome Treatments
US$ 1,195.00
This study covers the world outlook for Hunter syndrome treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P....
January 2026
288 pages
The 2027-2032 World Outlook for Hyaluronidase
US$ 1,195.00
This study covers the world outlook for hyaluronidase across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for th...
January 2026
287 pages
The 2027-2032 World Outlook for Hydroxychloroquine
US$ 1,195.00
This study covers the world outlook for hydroxychloroquine across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), f...
January 2026
287 pages
The 2027-2032 World Outlook for Hydroxychloroquine Sulphates
US$ 1,195.00
This study covers the world outlook for hydroxychloroquine sulphates across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (...
January 2026
288 pages
The 2027-2032 World Outlook for Hypercalcemia Treatments
US$ 1,195.00
This study covers the world outlook for hypercalcemia treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I....
January 2026
287 pages
The 2027-2032 World Outlook for Hyperhidrosis Treatments
US$ 1,195.00
This study covers the world outlook for hyperhidrosis treatments across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I....
January 2026
287 pages
The 2027-2032 World Outlook for Hyperimmune Globulins
US$ 1,195.00
This study covers the world outlook for hyperimmune globulins across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.)...
January 2026
287 pages
The 2027-2032 World Outlook for Hyperlipidemia Drugs
US$ 1,195.00
This study covers the world outlook for hyperlipidemia drugs across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.),...
January 2026
287 pages
